Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

- Last updated on GMT

Related tags: Vice president, Contract research organization

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Jeff Trotter, executive vice president of Phase IV development at PharmaNet, told Outsourcing-Pharma that “the real world is real important​”. In recent years post-market safety has become increasingly important, boosting Phase IV business for contract research organisations (CRO).

This is now being accompanied by increased focus on value. Trotter said this spans other indications, cost-effectiveness and comparative effectives. More and more regulators will request post-approval data to prove a product has lived up to promise, said Trotter.

In April PharmaNet made three executive appointments to its Phase IV team.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars